GANDHI AUTOMATIONS PVT LTD SEES 'HUGE' OPPORTUNITIES IN INDIA, SOUTHEAST ASIA, AFRICA

Due to this the South Asian and African pharmaceutical industry is witnessing a surge in tax reforms, turbulent equity markets, and the strengthening global economy. The growth of the pharmaceutical industry is boosted by healthcare digitalization and democratization, creating an explosion in patient data, and the emergence of value-based reimbursement models. The convergence of biopharmaceuticals, drug delivery devices, and companion diagnostics—enabled by digital connectivity—is driving regulatory and commercial changes in many exciting ways for the industry.   We also believe, small- to medium-sized merger and acquisition activities will increase. Post M&A and integration will differentiate the top-tier pharmaceutical companies from each other. I believe opportunity and risk co-exist. In Asia markets, we are optimistic due to the fragmented population, demand for qualified healthcare services, growing automation requirements and the growth of health insurance.   Regarding the India market, Indian pharmaceutical companies have a competitive advantage in generics. They will increase their competitiveness on the global pharmaceutical markets and create pressure for top-tier companies, particularly from their cost structure. In addition, as Indian companies invest more and more in production facilities throughout Africa, understanding more about these North-South and South-South partnerships and their associated knowledge and technology transfer policies becomes relevant. India’s approach to patent recognition is seen as a model that should be implemented in other developing countries.